UniQure has announced that the FDA has granted it the Regenerative Medicine Advanced Therapy (RMAT) designation for its developmental gene therapy for Huntington's disease.
The gene therapy, AMT-130, was tested in a Phase I/II trial with 21 patients for 24 months. The disease progression was measured using the composite Unified Huntington’s Disease Rating Scale. The company claims that in higher doses, AMT-130 slowed disease progression by 80%. The RMAT designation has been granted for the therapy following the reported positive results from the trials.
Based in the Netherlands, uniQure is a gene therapy company specializing in developing and commercializing adeno-associated virus (AAV) based therapies. The company aims to provide novel treatments for patients with severe genetic diseases. Its leading product, AMT-060, is a gene therapy for treating moderately severe hemophilia B. The company's pipeline includes AMT-130 for Huntington's disease and AMT-150 for Spinocerebellar Ataxia type 3. UniQure leverages its proprietary gene technology platform to develop, manufacture, and test these therapies, targeting liver-directed and central nervous system (CNS) disorders.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.